We are investigating the effects of sacituzumab tirumotecan in individuals with bladder cancer. This study aims to see how well this treatment works compared to standard options.
Health conditions and diseases that the clinical trial is designed to study and treat.
Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC) is a type of bladder cancer that is confined to the inner lining of the bladder and has a moderate risk of progression, requiring careful monitoring and treatment.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
